Disposition of 29400 shares by Orbimed Advisors Llc of Keros Therapeutics at 44.01 subject to Rule 16b-3
Slightly above 67% of Keros Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Keros Therapeutics suggests that many traders are alarmed. Keros Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Keros Therapeutics' earnings reports, geopolitical events, and overall market trends.
Keros |
Filed transaction by Keros Therapeutics Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Keros Therapeutics Fundamental Analysis
We analyze Keros Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Flow From Operations
Cash Flow From Operations Comparative Analysis
Keros Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Keros Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Keros Therapeutics stock to make a market-neutral strategy. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics with similar companies.
Peers
Keros Therapeutics Related Equities
| MLYS | Mineralys Therapeutics, | 1.56 | ||||
| AVTE | Aerovate Therapeutics | 1.19 | ||||
| GLUE | Monte Rosa | 0.13 | ||||
| HRMY | Harmony Biosciences | 0.45 | ||||
| REPL | Replimune | 0.51 | ||||
| EWTX | Edgewise Therapeutics | 0.53 | ||||
| SNDX | Syndax Pharmaceuticals | 1.16 | ||||
| IDYA | Ideaya Biosciences | 2.81 | ||||
| KZR | Kezar Life | 3.53 | ||||
| LRMR | Larimar Therapeutics | 3.70 | ||||
| ANAB | AnaptysBio | 4.07 | ||||
| FENC | Fennec Pharmaceuticals | 6.75 | ||||
| JANX | Janux Therapeutics | 7.52 | ||||
| MGTX | MeiraGTx Holdings | 8.75 | ||||
| IPSC | Century Therapeutics | 10.26 |
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.